Shopping Cart (0)
My Account

 Shopping Cart
Conferences | Training Courses | Market Reports | Managed Events | Past Conferences | Update Me
SELECTBIO Conferences Circulating DNA, Circulating RNA, Circulating Tumor Cells
Conferences  \  Circulating Biomarkers World Congress 2015  \  Circulating DNA, Circulating RNA, Circulating Tumor Cells  \  Agenda  \  Pavan Kumar
RegisterLogin

Pavan Kumar's Biography


Pavan Kumar, Senior Scientist, Eisai Inc

Dr. Kumar did his Ph.D. at University of California-Davis, followed by
working at Somagenics Inc, a start-up biotech where he focused on
developing a small RNA detection platform (miR-ID) that is now under
testing with various academic/industrial collaborators. Since then, he is
part of the Biomarkers and Personalized Medicine unit at Eisai Inc., where
in addition to supporting genomics based biomarker research and development
for clinical programs, he continues to work on discovery and validation of
circulating miRNA signatures for both CNS and Oncology indications.

Pavan Kumar Image

miRNAs as Circulating Diagnostic Biomarkers: The Promise and How We Can Get There

Tuesday, 24 March 2015 at 15:30

Add to Calendar ▼2015-03-24 15:30:002015-03-24 16:30:00Europe/LondonmiRNAs as Circulating Diagnostic Biomarkers: The Promise and How We Can Get ThereSELECTBIOenquiries@selectbiosciences.com

miRNAs have been an attractive class of biomarkers with a lot of studies published (especially over the last 5 years) demonstrating their potential diagnostic value in various disease indications. The presence of miRNAs in circulating body fluids in stable condition coupled with the rapid advances in the field of small RNA detection have positioned them as ideal biomarker candidates, be it for stand-alone diagnostics for diseases or as drug response or toxicology markers. But the promise of this exciting class of markers is also balanced with challenges in identifying reproducible miRNA signatures. The lack of reproducibility is due to many factors, including experimental design, site effects on sample handling and platform biases. A review of the challenges will be presented along with a case study comparing different profiling technologies, ending with a discussion on a robust profiling workflow, which would help in both discovery as well as validation of these miRNA signatures.

Add to Calendar ▼2015-03-23 00:00:002015-03-24 00:00:00Europe/LondonCirculating DNA, Circulating RNA, Circulating Tumor CellsSELECTBIOenquiries@selectbiosciences.com


Corporate Sponsors